What's Happening?
ParcelBio, a biotechnology company, announced it has raised $13 million in seed financing to develop its Amplified and Prolonged EXpression mRNA (APEXm) platform. The funding, led by Breyer Capital and other investors, will support the company's pipeline,
including an in vivo CAR T program for autoimmune diseases. ParcelBio's APEXm platform aims to enhance protein expression and durability, addressing limitations of current mRNA technologies. The company plans to present preclinical data at the American Society of Gene and Cell Therapy annual meeting, showcasing the platform's potential in achieving durable, drug-free remission in autoimmune diseases.
Why It's Important?
ParcelBio's development of the APEXm platform could significantly impact the field of mRNA therapeutics by overcoming current limitations in protein expression and durability. This advancement has the potential to enhance the effectiveness of treatments for autoimmune diseases and other conditions. The successful development of scalable, off-the-shelf therapies could lead to more accessible and cost-effective treatment options. The company's focus on in vivo CAR T therapies for autoimmune diseases highlights the potential for innovative approaches to achieve long-term remission, benefiting patients and the healthcare industry.
